Your browser doesn't support javascript.
loading
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer
Journal of Pathology and Translational Medicine ; : 355-363, 2015.
Article in English | WPRIM | ID: wpr-182015
ABSTRACT
With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Breast / Breast Neoplasms / Biomarkers / Lymphocytes, Tumor-Infiltrating / Treatment Outcome / Negotiating / Drug Therapy / Triple Negative Breast Neoplasms / ErbB Receptors / Immune System Type of study: Prognostic study Limits: Humans Language: English Journal: Journal of Pathology and Translational Medicine Year: 2015 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Breast / Breast Neoplasms / Biomarkers / Lymphocytes, Tumor-Infiltrating / Treatment Outcome / Negotiating / Drug Therapy / Triple Negative Breast Neoplasms / ErbB Receptors / Immune System Type of study: Prognostic study Limits: Humans Language: English Journal: Journal of Pathology and Translational Medicine Year: 2015 Type: Article